This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esche, C. Articles by Shurin, M. R. Search for Related Content PubMed PubMed Citation Articles by Esche, C. Articles by Shurin, M. R.

FLT3 Ligand Administration Inhibits Tumor Growth in Murine Melanoma and Lymphoma¹

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15261 [C. E., M. T. L., M. R. S.]; Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213 [V. M. S.]; and Immunex Corporation, Seattle, Washington 98101 [C. M.]

Successful treatment of melanoma and lymphoma may result from the induction of specific antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3 ligand (FL) results in a reversible accumulation of functionally active DCs in both lymphoid and nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL in murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all experiments, tumor growth was significantly inhibited by FL administration. Analysis by immunohistochemistry revealed an increase in the DC accumulation within B16 and EL-4 tumors after treatment with FL. No change was observed for CL8-1 melanoma. These data suggest a potential role for FL in the immunotherapy of malignant skin tumors and possible DC involvement in this effect.

¹ Supported by grants from the Deutsche Forschungsgemeinschaft (to C. E.), from the National Cancer Institute (to M. T. L.), and from the American Cancer Society (to M. R. S.).

² To whom requests for reprints should be addressed, at Department of Surgical Oncology, University of Pittsburgh Cancer Institute, 300 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213. Phone: (412) 692-4995; Fax: (412) 692-4997; E-mail: mshu@med.pitt.edu.

Received 10/16/97. Accepted 12/18/97.

This article has been cited by other articles:

				S. Sekine, K. Kataoka, Y. Fukuyama, Y. Adachi, J. Davydova, M. Yamamoto, R. Kobayashi, K. Fujihashi, H. Suzuki, D. T. Curiel, et al. A Novel Adenovirus Expressing Flt3 Ligand Enhances Mucosal Immunity by Inducing Mature Nasopharyngeal-Associated Lymphoreticular Tissue Dendritic Cell Migration J. Immunol., June 15, 2008; 180(12): 8126 - 8134. [Abstract] [Full Text] [PDF]

				A. Berhanu, J. Huang, S. M. Alber, S. C. Watkins, and W. J. Storkus Combinational FLt3 Ligand and Granulocyte Macrophage Colony-Stimulating Factor Treatment Promotes Enhanced Tumor Infiltration by Dendritic Cells and Antitumor CD8+ T-Cell Cross-priming but Is Ineffective as a Therapy. Cancer Res., May 1, 2006; 66(9): 4895 - 4903. [Abstract] [Full Text] [PDF]

				U. I. Chaudhry, S. C. Katz, T. P. Kingham, V. G. Pillarisetty, J. R. Raab, A. B. Shah, and R. P. DeMatteo In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells FASEB J, May 1, 2006; 20(7): 982 - 984. [Abstract] [Full Text] [PDF]

				R. S. Freedman, S. Vadhan-Raj, C. Butts, C. Savary, B. Melichar, C. Verschraegen, J. J. Kavanagh, M. E. Hicks, L. B. Levy, J. K. Folloder, et al. Pilot Study of Flt3 Ligand Comparing Intraperitoneal with Subcutaneous Routes on Hematologic and Immunologic Responses in Patients with Peritoneal Carcinomatosis and Mesotheliomas Clin. Cancer Res., November 1, 2003; 9(14): 5228 - 5237. [Abstract] [Full Text] [PDF]

				D. G. Gilliland and J. D. Griffin The roles of FLT3 in hematopoiesis and leukemia Blood, August 13, 2002; 100(5): 1532 - 1542. [Abstract] [Full Text] [PDF]

				P. Parajuli, V. Pisarev, J. Sublet, A. Steffel, M. Varney, R. Singh, D. LaFace, and J. E. Talmadge Immunization with Wild-Type p53 Gene Sequences Coadministered with Flt3 Ligand Induces an Antigen-specific Type 1 T-Cell Response Cancer Res., November 1, 2001; 61(22): 8227 - 8234. [Abstract] [Full Text] [PDF]

				Z. K. Ballas, A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs J. Immunol., November 1, 2001; 167(9): 4878 - 4886. [Abstract] [Full Text] [PDF]

				I. B. Kremer, M. P. Gould, K. D. Cooper, and F. P. Heinzel Pretreatment with Recombinant Flt3 Ligand Partially Protects against Progressive Cutaneous Leishmaniasis in Susceptible BALB/c Mice Infect. Immun., February 1, 2001; 69(2): 673 - 680. [Abstract] [Full Text] [PDF]

				C.-F. Hung, K.-F. Hsu, W.-F. Cheng, C.-Y. Chai, L. He, M. Ling, and T-C. Wu Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to a Gene Encoding the Extracellular Domain of Fms-like Tyrosine Kinase 3-Ligand Cancer Res., February 1, 2001; 61(3): 1080 - 1088. [Abstract] [Full Text]

				M. A. Morse, S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, P. Mosca, T. Clay, R. I. Cumming, et al. Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3883 - 3893. [Abstract] [Full Text] [PDF]

				N. Mach, S. Gillessen, S. B. Wilson, C. Sheehan, M. Mihm, and G. Dranoff Differences in Dendritic Cells Stimulated in Vivo by Tumors Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor or Flt3-Ligand Cancer Res., June 1, 2000; 60(12): 3239 - 3246. [Abstract] [Full Text]

				H. J. McKenna, K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells Blood, June 1, 2000; 95(11): 3489 - 3497. [Abstract] [Full Text] [PDF]

				A. Wang, S. E. Braun, G. Sonpavde, and K. Cornetta Antileukemic Activity of Flt3 Ligand in Murine Leukemia Cancer Res., April 1, 2000; 60(7): 1895 - 1900. [Abstract] [Full Text]

				M. D. Roth, B. J. Gitlitz, S. M. Kiertscher, A. N. Park, M. Mendenhall, N. Moldawer, and R. A. Figlin Granulocyte Macrophage Colony-stimulating Factor and Interleukin 4 Enhance the Number and Antigen-presenting Activity of Circulating CD14+ and CD83+ Cells in Cancer Patients Cancer Res., April 1, 2000; 60(7): 1934 - 1941. [Abstract] [Full Text]

				J. E. Ohm, M. R. Shurin, C. Esche, M. T. Lotze, D. P. Carbone, and D. I. Gabrilovich Effect of Vascular Endothelial Growth Factor and FLT3 Ligand on Dendritic Cell Generation In Vivo J. Immunol., September 15, 1999; 163(6): 3260 - 3268. [Abstract] [Full Text] [PDF]

				N. S. Williams, J. Klem, I. J. Puzanov, P. V. Sivakumar, M. Bennett, and V. Kumar Differentiation of NK1.1+, Ly49+ NK Cells from flt3+ Multipotent Marrow Progenitor Cells J. Immunol., September 1, 1999; 163(5): 2648 - 2656. [Abstract] [Full Text] [PDF]

				J.-M. Peron, C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells J. Immunol., December 1, 1998; 161(11): 6164 - 6170. [Abstract] [Full Text] [PDF]